TLS prophylactic strategies, by dose escalation, in all patients
| Prophylactic agent used . | Dose escalation (for all patients) . | |||||
|---|---|---|---|---|---|---|
| 1, N = 136∗ . | 2, N = 136∗ . | 3, N = 136∗ . | 4, N = 136∗ . | 5, N = 136∗ . | 6, N = 136∗ . | |
| Allopurinol | 116/135 (86%) | 118/132 (89%) | 110/122 (90%) | 102/115 (89%) | 97/111 (87%) | 1/1 (100%) |
| Febuxostat | 6/135 (4.4%) | 4/132 (3.0%) | 5/122 (4.1%) | 5/115 (4.3%) | 5/111 (4.5%) | 0/1 (0%) |
| IV hydration | 96/135 (71%) | 91/132 (69%) | 76/122 (62%) | 64/115 (56%) | 58/111 (52%) | 0/1 (0%) |
| IV diuretic use | 17/135 (13%) | 13/132 (9.8%) | 8/122 (6.6%) | 6/115 (5.2%) | 7/111 (6.3%) | 0/1 (0%) |
| Rasburicase | 13/135 (9.6%) | 7/132 (5.3%) | 4/122 (3.3%) | 4/115 (3.5%) | 3/111 (2.7%) | 0/1 (0%) |
| Phosphate binders | 24/135 (18%) | 26/132 (20%) | 25/122 (20%) | 25/115 (22%) | 19/111 (17%) | 1/1 (100%) |
| Ion exchange resins | 13/135 (9.6%) | 7/132 (5.3%) | 6/122 (4.9%) | 5/115 (4.3%) | 2/111 (1.8%) | 0/1 (0%) |
| Prophylactic agent used . | Dose escalation (for all patients) . | |||||
|---|---|---|---|---|---|---|
| 1, N = 136∗ . | 2, N = 136∗ . | 3, N = 136∗ . | 4, N = 136∗ . | 5, N = 136∗ . | 6, N = 136∗ . | |
| Allopurinol | 116/135 (86%) | 118/132 (89%) | 110/122 (90%) | 102/115 (89%) | 97/111 (87%) | 1/1 (100%) |
| Febuxostat | 6/135 (4.4%) | 4/132 (3.0%) | 5/122 (4.1%) | 5/115 (4.3%) | 5/111 (4.5%) | 0/1 (0%) |
| IV hydration | 96/135 (71%) | 91/132 (69%) | 76/122 (62%) | 64/115 (56%) | 58/111 (52%) | 0/1 (0%) |
| IV diuretic use | 17/135 (13%) | 13/132 (9.8%) | 8/122 (6.6%) | 6/115 (5.2%) | 7/111 (6.3%) | 0/1 (0%) |
| Rasburicase | 13/135 (9.6%) | 7/132 (5.3%) | 4/122 (3.3%) | 4/115 (3.5%) | 3/111 (2.7%) | 0/1 (0%) |
| Phosphate binders | 24/135 (18%) | 26/132 (20%) | 25/122 (20%) | 25/115 (22%) | 19/111 (17%) | 1/1 (100%) |
| Ion exchange resins | 13/135 (9.6%) | 7/132 (5.3%) | 6/122 (4.9%) | 5/115 (4.3%) | 2/111 (1.8%) | 0/1 (0%) |
n/N (%).